氯马斯汀对新生羊缺氧缺血性脑病模型神经生理结局的影响。
Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy.
作者信息
Mike Jana Krystofova, White Yasmine, Hutchings Rachel S, Vento Christian, Ha Janica, Iranmahboub Ariana, Manzoor Hadiya, Gunewardena Anya, Cheah Cheryl, Wang Aijun, Goudy Brian D, Lakshminrusimha Satyan, Long-Boyle Janel, Fineman Jeffrey R, Ferriero Donna M, Maltepe Emin
机构信息
Department of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA.
Department of Biomedical Engineering, University of California Davis, Davis, CA 95817, USA.
出版信息
Children (Basel). 2023 Oct 25;10(11):1728. doi: 10.3390/children10111728.
Originally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis. Here, we conducted an in-depth analysis of the feasibility, safety, and neuroprotective efficacy of clemastine administration in near-term lambs ( = 25, 141-143 days) following a global ischemic insult induced via an umbilical cord occlusion (UCO) model. Lambs were randomly assigned to receive clemastine or placebo postnatally, and outcomes were assessed over a six-day period. Clemastine administration was well tolerated. While treated lambs demonstrated improvements in inflammatory scores, their neurodevelopmental outcomes were unchanged.
氯马斯汀最初因其抗组胺特性而被美国食品药品监督管理局（FDA）批准使用，它还能促进白质完整性，并且在治疗诸如多发性硬化症等脱髓鞘疾病方面显示出前景。在此，我们对通过脐带闭塞（UCO）模型诱导全脑缺血损伤后的近足月羔羊（n = 25，141 - 143天）给予氯马斯汀的可行性、安全性和神经保护功效进行了深入分析。羔羊出生后被随机分配接受氯马斯汀或安慰剂治疗，并在六天内评估结果。氯马斯汀给药耐受性良好。虽然接受治疗的羔羊炎症评分有所改善，但其神经发育结果未发生变化。
Zotero 插件